Why 2017 Was a Year to Remember for Juno Therapeutics – Motley Fool
|
Why 2017 Was a Year to Remember for Juno Therapeutics
Motley Fool JCAR017, the new star of Juno's pipeline, uses the same basic principle as JCAR015; both are chimeric antigen receptor T–cell (CAR-T) therapies that train T–cells to target cancerous cells expressing a protein called CD19, but JCAR017 uses a fixed … |
